Invicro has a vast range of tools that help accelerate your drug discovery and development process. Our technology platforms support key decision-making in:

  • Early discovery and screening
  • Candidate selection
  • First-in-human translation and early development
  • Late stage, multi-center determination of efficacy

We have experience working with a wide range of therapeutics, including small molecules, peptides, proteins, antibodies, multi-specific proteins, CAR-T cells, viruses, antisense oligonucleotides (ASO), DNA, RNA and others. Invicro strives to answer a wide array of biological questions, including but not limited to:

  • Target identification
  • Target density (Bmax)
  • Binding affinity (KD)
  • Target engagement
  • Target occupancy, impact of dosing regimens, and route of administration
  • Biodistribution and pharmacokinetics (ADME, DMPK)
  • Pharmacodynamics (PD)
  • Efficacy


Invicro offers in vitro assays, in vivo imaging and ex vivo tissue imaging across resolutions and sensitivities. We design studies that combine different technologies spanning various platforms, including:

in vivo


  • IVIS Bioluminescence
  • IVIS Fluorescence
  • Fluorescence Molecular Tomography (FMT)
  • Optoacoustic Tomography (MSOT)


  • MRI
  • PET
  • CT
  • Ultrasound

Rodent Models

  • AAALAC accredited facilities
  • All Major Disease Areas
  • All Major Tumor Models

Larger Species

  • All Major Research Species
  • Clinical Imaging
  • Veterinary Radiology

ex vivo

Imaging and Radioisotopes

  • Cryo-fluorescence tomography (CFT)
  • ex vivo fluorescence reflectance imaging
  • Confocal microscopy
  • Autoradiography & micro-autoradiography
  • Homogenate radioligand binding assays
  • Gamma counting and liquid scintillation


  • Core histology
  • Specialty stains
  • Multiplex Immunohistochemistry (IHC)
  • Multiplex Immunofluorescence (IF)
  • RNAScope® ISH
  • BaseScope™ ISH
  • Quanticell™ High sensitivity Immunohistochemistry (IHC)
  • Pathologist interpretation
  • Whole Side Imaging (WSI)
  • Image analysis
  • CAP-CLIA assay development and validation
  • Companion Diagnostic (CDx) development
  • Digital biomarker development


  • Flow cytometry
  • Clinical chemistry
  • CBC Analysis
  • Urinalysis

in vitro and Chemistry

In Vitro Assays

  • Cell Culture
  • Cell binding and competition
  • Internalization
  • Tissue homogenate binding

Imaging Agent Chemistry

  • Imaging agent radiolabeling
    • Oligos to Antibodies
    • Nanoparticles
    • Viruses
    • Cells
  • Fluorescent labeling


Invicro leverages advanced tools to provide solutions to various questions in preclinical animal models (rodent to NHP) and in translational work in humans, including:


  • What is the in vivo distribution of a compound following intrathecal administration?
  • Does a compound cross the BBB?
  • What is the rate of clearance and route of elimination of a novel antisense oligonucleotide (ASO)?
  • What is the fate of the cargo with respect to the carrier (e.g., for an antibody drug conjugate or a drug loaded liposome)?
  • What is the integrity of a novel implant material over time?
  • Does a novel alpha radiopharmaceutical exhibit tumor cell internalization in vivo?
  • What is the fate and persistence of my therapeutic T cells?
  • Where and for how long is my gene of interest delivered and expressed?

PD biomarkers and efficacy

  • Does my anti-cancer therapeutic inhibit tumor growth in an orthotopic, transgenic, or metastatic tumor model?
  • Can tumor accumulation of a novel radiolabeled compound predict treatment response?
  • Are there synergistic effects when combining an alpha radiopharmaceutical with an immunotherapy agent?
  • Does colon wall thickness in an animal model of IBD change following treatment?
  • Does my anticancer therapeutic decrease tumor burden in my deep tissue tumor model?
  • Does liver fat fraction or fibrosis stabilize or decrease with my treatment?
  • Does my immune-modulator increase T cell activation in a tumor, and with what timing?

Target Validation/Engagement

  • What is the receptor occupancy of a compound following oral dosing?
  • Does my targeted biologic bind preferentially in a target expressing tumor vs. a target negative tumor?
  • Does my novel drug delivery system (e.g. virus) reach its target in vivo?


  • What is the estimated human dosimetry (absorbed dose) for a novel radiotracer?
  • Is there angiogenesis surrounding a surgical implant?